drugset / Trial / NCT04484922

Dexmedetomidine Neuroprotection in Pediatric Cardiac Surgery

NCT04484922 ↗

Unknown 160 enrolled Seoul National University Hospital
RandomizedParallel-groupQuadruple-blindPrevention

Summary

Neurodevelopmental disability is the most significant complication for survivors of infant surgery for congenital heart disease. In this study we sought to determine if intraoperative continuous infusion of dexmedetomidine are associated with neurodevelopmental outcomes at 12 months.

Timeline

Start
2020-08-25
Primary completion
2023-05-31
Completion
2023-05-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexmedetomidine Other / unclassified 0.5 ug/kg Other